Marc Began - ABIOMED Gen VP
Insider
Marc Began is Gen VP of ABIOMED
| Age | 56 |
| Phone | 978 777-8411 |
| Web | www.abiomed.com |
Marc Began Latest Insider Activity
Tracking and analyzing the buying and selling activities of Marc Began against ABIOMED stock is an integral part of due diligence when investing in ABIOMED. Marc Began insider activity provides valuable insight into whether ABIOMED is net buyers or sellers over its current business cycle. Note, ABIOMED insiders must abide by specific rules, including filing SEC forms every time they buy or sell ABIOMED'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Marc Began over six months ago Disposition of 90000 shares by Marc Began of Axogen at 8.16 subject to Rule 16b-3 | ||
Marc Began over six months ago Disposition of 90000 shares by Marc Began of Axogen at 8.16 subject to Rule 16b-3 | ||
Marc Began over six months ago Disposition of 90000 shares by Marc Began of Axogen at 8.16 subject to Rule 16b-3 | ||
Marc Began over six months ago Disposition of 90000 shares by Marc Began of Axogen at 8.16 subject to Rule 16b-3 |
ABIOMED Management Efficiency
The company has return on total asset (ROA) of 0.0955 % which means that it generated a profit of $0.0955 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1824 %, meaning that it created $0.1824 on every $100 dollars invested by stockholders. ABIOMED's management efficiency ratios could be used to measure how well ABIOMED manages its routine affairs as well as how well it operates its assets and liabilities.ABIOMED currently holds 10 M in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. ABIOMED has a current ratio of 7.38, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about ABIOMED's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Jannick Thomsen | Sealed Air | 41 | |
| Loic Tassel | Procter Gamble | N/A | |
| James Woidke | Eastern Co | 61 | |
| Suzanne Rowland | Sealed Air | 58 | |
| Christine McCarthy | Procter Gamble | 65 | |
| Ashraf Malik | CF Industries Holdings | 58 | |
| Sundar Raman | Procter Gamble | N/A | |
| Fatima Francisco | Procter Gamble | 55 | |
| Monica Turner | Procter Gamble | 58 | |
| Andrew Hedberg | Ecolab Inc | N/A | |
| Michael Doss | Sealed Air | 54 | |
| B Allen | Procter Gamble | 47 | |
| Debra Lee | Procter Gamble | 66 | |
| M Grabowski | Procter Gamble | 52 | |
| Christopher Moulton | Eastern Co | N/A | |
| Laura Becker | Procter Gamble | N/A | |
| Y Pek | Acme United | N/A | |
| Danielle McCoy | Steven Madden | N/A | |
| Nicholas Vlahos | Eastern Co | 42 | |
| Yang Shuxian | Sealed Air | N/A | |
| Linda Dempsey | CF Industries Holdings | 60 | |
Management Performance
| Return On Equity | 0.18 | |||
| Return On Asset | 0.0955 |
ABIOMED Leadership Team
Elected by the shareholders, the ABIOMED's board of directors comprises two types of representatives: ABIOMED inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ABIOMED. The board's role is to monitor ABIOMED's management team and ensure that shareholders' interests are well served. ABIOMED's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ABIOMED's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Michael Howley, VP and General Manager of Global Sales | ||
| Michael Minogue, Chairman, CEO and President Member of Special Stock Option Committee and Member of Executive Committee | ||
| Andrew Greenfield, Vice President - Healthcare Solutions | ||
| Thorsten Siess, Ex Officer | ||
| Ingrid Ward, Director Relations | ||
| Matthew Plano, Ex Integration | ||
| Todd Trapp, CFO, Vice President | ||
| Sarah Karr, Communications Mang | ||
| Marc Began, Gen VP | ||
| David Weber, Scientific Advisor |
ABIOMED Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is ABIOMED a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.18 | |||
| Return On Asset | 0.0955 | |||
| Profit Margin | 0.25 % | |||
| Operating Margin | 0.23 % | |||
| Current Valuation | 16.32 B | |||
| Shares Outstanding | 45.09 M | |||
| Shares Owned By Insiders | 2.02 % | |||
| Shares Owned By Institutions | 97.00 % | |||
| Number Of Shares Shorted | 753.62 K | |||
| Price To Earning | 76.38 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Other Consideration for investing in ABIOMED Stock
If you are still planning to invest in ABIOMED check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the ABIOMED's history and understand the potential risks before investing.
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators |